Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences, Inc.

< Previous 1 2 3 4 5 Next >
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Host Investor Day on Sept. 20, 2022
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Second Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Honored with a 2022 Arizona Top Workplace Award
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Support for OHSU’s War on Melanoma™
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the JMP Securities Life Sciences Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.